Bailard’s Quest Diagnostics DGX Stock Holding History

Bailard’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.09M	Buy	5,545 +1,499	+37%	+$291K	0.03%	313
2025 Q4	$702K	Buy	+4,046	New	+$737K	0.02%	401
2021 Q2	–	Sell	-2,668	Closed	-$342K	–	716
2021 Q1	$342K	Sell	2,668 -37,868	-93%	-$4.67M	0.01%	472
2020 Q4	$4.83M	Buy	40,536 +378	+0.9%	+$46.1K	0.22%	93
2020 Q3	$4.6M	Buy	40,158 +867	+2%	+$102K	0.24%	84
2020 Q2	$4.48M	Buy	39,291 +3,995	+11%	+$424K	0.25%	83
2020 Q1	$2.83M	Buy	35,296 +5,502	+18%	+$570K	0.2%	100
2019 Q4	$3.18M	Buy	29,794 +7,520	+34%	+$784K	0.18%	114
2019 Q3	$2.38M	Buy	22,274 +1,709	+8%	+$175K	0.14%	139
2019 Q2	$2.09M	Buy	20,565 +882	+4%	+$84.8K	0.13%	155
2019 Q1	$1.77M	Sell	19,683 -68	-0.3%	-$5.89K	0.11%	165
2018 Q4	$1.65M	Sell	19,751 -14,664	-43%	-$1.37M	0.11%	162
2018 Q3	$3.71M	Sell	34,415 -476	-1%	-$52.2K	0.22%	101
2018 Q2	$3.84M	Buy	+34,891	New	+$3.63M	0.23%	99

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Bailard's DGX Position: Q1 2026 in Review

Bailard increased its Quest Diagnostics (DGX) stake by 37% in Q1 2026, buying an estimated $291K and bringing the position to 5,545 shares worth $1.09M. The position accounts for 0.03% of the portfolio, ranked #313.

Bailard first reported a position in DGX in Q2 2018 and has held it in 14 quarters since. The position peaked at $4.83M in Q4 2020. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Bailard held 5,545 shares of Quest Diagnostics worth $1.09M as of Q1 2026.
Bailard bought 1,499 Quest Diagnostics shares in Q1 2026, an estimated $291K.
Quest Diagnostics made up 0.03% of Bailard's portfolio in Q1 2026, its #313 holding.
Bailard first reported a position in Quest Diagnostics in Q2 2018 and has held it in 14 quarters since.
Bailard's Quest Diagnostics position peaked at $4.83M in Q4 2020.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.